Jade Biosciences (NASDAQ:JBIO) Stock Price Down 4.7% - What's Next?

Key Points

• Jade Biosciences shares fell 4.7% to about $18.24, with trading volume below its average. The company has a market capitalization of approximately $1.14 billion.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $51.75; targets range from $45 to $77.
• The clinical-stage biotechnology company reported quarterly EPS of -$0.76, missing expectations of -$0.66, while analysts anticipate a full-year EPS loss of approximately $2.84.

Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report)'s share price was down 4.7% during trading on Friday . The company traded as low as $18.28 and last traded at $18.2350. Approximately 550,875 shares traded hands during trading, a decline of 24% from the average session volume of 724,332 shares. The stock had previously closed at $19.14.

Analysts Set New Price Targets

Several analysts have issued reports on the company. BTIG Research upped their target price on Jade Biosciences from $74.00 to $77.00 and gave the company a "buy" rating in a report on Monday, August 10th. UBS Group started coverage on shares of Jade Biosciences in a research report on Monday, June 15th. They set a "buy" rating and a $45.00 price target on the stock. Wedbush boosted their price target on shares of Jade Biosciences from $45.00 to $47.00 and gave the company an "outperform" rating in a research report on Monday, August 10th. Weiss Ratings lowered shares of Jade Biosciences from a "sell (d)" rating to a "sell (d-)" rating in a report on Tuesday, June 16th. Finally, HC Wainwright raised their price objective on shares of Jade Biosciences from $45.00 to $55.00 and gave the stock a "buy" rating in a research report on Monday, June 1st. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $51.75.

Jade Biosciences Stock Down 6.4%

The company has a market capitalization of $1.14 billion, a PE ratio of -9.33 and a beta of 1.45. The firm has a 50-day moving average of $21.15 and a two-hundred day moving average of $19.56.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.10). On average, equities research analysts expect that Jade Biosciences, Inc. will post -2.84 EPS for the current year.

Institutional Trading of Jade Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of JBIO. Legal & General Group Plc purchased a new position in Jade Biosciences during the second quarter worth about $29,000. Russell Investments Group Ltd. acquired a new position in shares of Jade Biosciences in the 2nd quarter worth approximately $31,000. BNP Paribas Financial Markets acquired a new position in shares of Jade Biosciences in the 2nd quarter worth approximately $32,000. California State Teachers Retirement System boosted its position in shares of Jade Biosciences by 40.3% during the 4th quarter. California State Teachers Retirement System now owns 2,850 shares of the company's stock worth $44,000 after purchasing an additional 819 shares during the period. Finally, Group One Trading LLC increased its holdings in Jade Biosciences by 122.9% in the 4th quarter. Group One Trading LLC now owns 4,195 shares of the company's stock valued at $65,000 after purchasing an additional 22,527 shares during the last quarter.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.